Otava Alzheimer’s Disease Targeted Libraries
In this collection of targeted libraries we included those activities which can be divided into two Alzheimer’s treatment categories: (i) disease-modifying treatments that target and reduce the secondary pathologies of the disease, leading to the cessation or the reversal of disease progression; and (ii) symptomatic treatments that treat cognitive symptoms of the disease and protect from further cognitive decline.
We hope that Otava Targeted Libraries can help scientists and pharmaceutical companies racing to develop treatments that address the underlying Alzheimer’s disease processes.
OTAVA Ltd. is an international science-based chemical company founded in 1997 with production laboratories and offices in Europe (Kiev, Ukraine) and North America (Toronto, Canada).
Our company carries a diverse set of products and services for pharmaceutical companies, universities, research institutes and government agencies. We specialize in the development and production of featured chemicals, bio-chemicals and bioanalytical reagents.
Our newly created well-equipped kilo-lab provides multi-kilo scale-up preparation service for the clients.
Our facilities and highly-experienced personnel make possible a variety of contract research projects and custom syntheses of complex biologically active substances. Our Molecular Modelling Department provides the full range of advanced computational services.
150 Zabolotnogo St.
Kyiv 143, 03143
This release was published on openPR.
Permanent link to this press release:
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release Otava Alzheimer’s Disease Targeted Libraries here
News-ID: 188665 • Views: 1381
More Releases from Otava Ltd.
Search Otava Chemical Collections On-Line
In recent years, remarkable progress has been made and miraculous results produced in the field of synthetic chemistry. However, searching for desired chemical compounds among variety of chemical databases becomes more and more complex. Otava Ltd., a leading provider of synthetic organic compounds for research and drug discovery, - offers a number of products including focused libraries, screening compounds libraries and chemical building blocks. Our combined databases comprise more
More Releases for Alzheimer’s
Global Alzheimer’s disease, Dementia and Ageing Awareness
Lexis brings in a new spin on conferences by presenting the latest scientific improvements in the fields of Neurology and Neuroscience. Zurich is all set for an amazing event as LEXIS proudly presents the “Global Alzheimers, Dementia and Ageing Awareness” slated on July 17-18, 2019 at Zurich, Switzerland. The theme of the conference is “Global Voice and Awareness on Alzheimers Disease and Dementia Care”. Avenue Roger VAndendriessche, 18 at 1150 BRUSSELS Avenue
Global Alzheimer’s disease (AD) Market to 2024
Market Overview, Key in-line Products, Market Share Distribution, Competitive Dynamics, Regulatory Outlook, Pipeline Development, Growth Catalysts & Challenges, Leading Market & R&D Trends, Partnership & Deals Analyses, Global Sales forecast of in-line and pipeline products, Fast Growing Private Companies, Management Perspectives, Commentaries, Market Outlook & Summary Conclusions Global Alzheimer’s disease (AD) market was valued at $3.1bn in 2015 and is forecast to grow at a modest 5.3% CAGR between 2015
Europe Alzheimer’s Drug Pipeline Analysis
The incidence of Alzheimer’s disease has been on a rise in Europe in recent years and it most likely to continue rising in the near future. It has been observed that close to 50% of dependency of aged people in Europe is attributed for by Alzheimer’s disease. The rapid growth in the prevalence of Alzheimer's disease over the next few decades in Europe is expected to result in immense pressure
Alzheimer’s Disease Therapeutics Market Forecast – (2016-2020)
Alzheimer’s Disease Therapeutics in Major Developed Markets to 2021 - Aging Population and Improved Disease Understanding Increase Demand for Disease Modifying Agents Summary of the report: Alzheimer's Disease (AD) is an irreversible, progressive neurodegenerative disease, characterized by cognitive impairment, memory loss and functional decline. Symptoms typically begin to first appear in patients in their mid-sixties, with symptoms appearing in varying stages. The pathological features of AD comprise histopathological changes within the brain.
Alzheimer’s Association Long Island Presents Public Input Session for National …
On August 24, Alzheimer’s Association Long Island will hold a public input session to solicit views, comments and perspectives from stakeholders in the Alzheimer’s community to assist in the development of a successful National Alzheimer’s Plan. The recommendations and comments expressed during these input sessions, taking place across the country in August, will be collected and shared this fall with officials from the U.S. Department of Health and Human Services,
Senior Helpers Joins the Alzheimer’s Association Alzheimer’s Early Detection …
Towson, MD– January 2010 – Senior Helpers, the nation’s fastest growing provider of in-home care for seniors, announced today their participation in the Alzheimer’s Association Alzheimer’s Early Detection Alliance (AEDA). Senior Helpers has become a “Champion” with the AEDA and will work to spread the word about the warning signs of Alzheimer’s. The AEDA is an Alzheimer’s Association national outreach campaign focusing on the 10 Warning Signs of Alzheimer’s disease. The